Clinical Trial: Combination of APG-2575, Olverembatinib (HQP1351), Liposome Mitoxantrone and Homoharringtonine(MHO2575) in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia (China)

China, Aug. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Combination of APG-2575, Olverembatinib (HQP1351), Liposome Mitoxantrone and Homoharringtonine(MHO2575) in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129913

Registration Time: 2026/08/11

Type: Interventional study

Primary Sponsor: Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=218654

Published by HT Digital Content Services with permission from Health Daily Digest....